AAI
Cambridge, MA, United States
AAI
Cambridge, MA, United States

Time filter

Source Type

NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN) (“Kadmon” or the “Company”) today announced the presentation of data from its completed Phase 2 clinical trial of KD025, the Company’s oral Rho-associated coiled-coil kinase 2 (“ROCK2”) inhibitor, in patients with moderate to severe psoriasis, as well as new preclinical data demonstrating the importance of ROCK2 signaling in regulating the pro-inflammatory aspect of immune response. The data will be presented in oral and poster presentations at the American Association of Immunologists (AAI) Annual Meeting, taking place May 12-16, 2017, in Washington, D.C. “The data from these studies provide further support for ROCK2 inhibition as a therapeutic approach in autoimmune diseases,” said Alexandra Zanin-Zhorov, PhD, Vice President, Head of Immunology at Kadmon and a lead author on the studies. “ROCK2 signaling represents an important target in autoimmunity, as it regulates STAT3 phosphorylation and transcriptional activity in human T cells, both key contributors to autoimmune conditions.” “The findings from our completed Phase 2 study of KD025 in psoriasis, which were recently published in the Journal of Immunology, together with the new mechanistic preclinical data, underscore the importance of ROCK2 signaling in controlling auto-aggressive immune responses and support the clinical development of KD025 in autoimmune indications,” said Harlan W. Waksal, President and Chief Executive Officer at Kadmon. “We remain enthusiastic about KD025’s therapeutic potential in autoimmunity and we look forward to announcing data from our ongoing Phase 2 trials in chronic graft-versus-host disease and in moderate to severe psoriasis in the second half of this year.” In the Company’s completed Phase 2 study, ROCK2 inhibition with KD025 improved clinical scores and skin pathology in psoriasis patients via concurrent modulation of the pro- and anti-inflammatory immune cell response. The new preclinical data describe the mechanism by which ROCK2 mediates activation of STAT3, a key regulator of the inflammatory pathway, and subsequent transcriptional activity during the induction of pro-inflammatory T cells. Specifically, researchers demonstrated that ROCK2 binds to STAT3 and regulates the transcription of specific genes that control pro-inflammatory T helper 17 (Th17) cell and T follicular helper (Tfh) cell function. These findings highlight the importance of ROCK2 signaling in controlling auto-aggressive immune responses. Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology and genetic diseases. This press release contains forward-looking statements. Such statements may be preceded by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel; (xx) our ability to achieve cost savings and other benefits from our efforts to streamline our operations and to not harm our business with such efforts; and (xxi) the use of proceeds from our recent private placement. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K filed pursuant to Section 13 of the Securities Exchange Act of 1934, as amended, with the SEC on March 22, 2017. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Wiseguyreports.Com Adds “Unmanned Aerial Vehicle System -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database Global Unmanned Aerial Vehicle System market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including Boeing PARROT 3DR Titan Aerospace AAI Northrop Grumman IAI Dynali helicopters BAE System SAGEM Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Unmanned Aerial Vehicle System in these regions, from 2012 to 2022 (forecast), covering On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Fixed-wing UAV Rotary wing UAV Flapping-wing UAV Airship UAV On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Unmanned Aerial Vehicle System for each application, including Military UAV Civilian UAV If you have any special requirements, please let us know and we will offer you the report as you want. Global Unmanned Aerial Vehicle System Market Research Report 2017 1 Unmanned Aerial Vehicle System Market Overview 1.1 Product Overview and Scope of Unmanned Aerial Vehicle System 1.2 Unmanned Aerial Vehicle System Segment by Type (Product Category) 1.2.1 Global Unmanned Aerial Vehicle System Production and CAGR (%) Comparison by Type (Product Category) (2012-2022) 1.2.2 Global Unmanned Aerial Vehicle System Production Market Share by Type (Product Category) in 2016 1.2.3 Fixed-wing UAV 1.2.4 Rotary wing UAV 1.2.5 Flapping-wing UAV 1.2.6 Airship UAV 1.3 Global Unmanned Aerial Vehicle System Segment by Application 1.3.1 Unmanned Aerial Vehicle System Consumption (Sales) Comparison by Application (2012-2022) 1.3.2 Military UAV 1.3.3 Civilian UAV 1.4 Global Unmanned Aerial Vehicle System Market by Region (2012-2022) 1.4.1 Global Unmanned Aerial Vehicle System Market Size (Value) and CAGR (%) Comparison by Region (2012-2022) 1.4.2 North America Status and Prospect (2012-2022) 1.4.3 Europe Status and Prospect (2012-2022) 1.4.4 China Status and Prospect (2012-2022) 1.4.5 Japan Status and Prospect (2012-2022) 1.4.6 Southeast Asia Status and Prospect (2012-2022) 1.4.7 India Status and Prospect (2012-2022) 1.5 Global Market Size (Value) of Unmanned Aerial Vehicle System (2012-2022) 1.5.1 Global Unmanned Aerial Vehicle System Revenue Status and Outlook (2012-2022) 1.5.2 Global Unmanned Aerial Vehicle System Capacity, Production Status and Outlook (2012-2022) 7 Global Unmanned Aerial Vehicle System Manufacturers Profiles/Analysis 7.1 Boeing 7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.1.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.1.2.1 Product A 7.1.2.2 Product B 7.1.3 Boeing Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.1.4 Main Business/Business Overview 7.2 PARROT 7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.2.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.2.2.1 Product A 7.2.2.2 Product B 7.2.3 PARROT Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.2.4 Main Business/Business Overview 7.3 3DR 7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.3.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.3.2.1 Product A 7.3.2.2 Product B 7.3.3 3DR Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.3.4 Main Business/Business Overview 7.4 Titan Aerospace 7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.4.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.4.2.1 Product A 7.4.2.2 Product B 7.4.3 Titan Aerospace Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.4.4 Main Business/Business Overview 7.5 AAI 7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.5.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.5.2.1 Product A 7.5.2.2 Product B 7.5.3 AAI Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.5.4 Main Business/Business Overview 7.6 Northrop Grumman 7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.6.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.6.2.1 Product A 7.6.2.2 Product B 7.6.3 Northrop Grumman Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.6.4 Main Business/Business Overview 7.7 IAI 7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.7.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.7.2.1 Product A 7.7.2.2 Product B 7.7.3 IAI Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.7.4 Main Business/Business Overview 7.8 Dynali helicopters 7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.8.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.8.2.1 Product A 7.8.2.2 Product B 7.8.3 Dynali helicopters Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.8.4 Main Business/Business Overview 7.9 BAE System 7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.9.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.9.2.1 Product A 7.9.2.2 Product B 7.9.3 BAE System Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.9.4 Main Business/Business Overview 7.10 SAGEM 7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.10.2 Unmanned Aerial Vehicle System Product Category, Application and Specification 7.10.2.1 Product A 7.10.2.2 Product B 7.10.3 SAGEM Unmanned Aerial Vehicle System Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.10.4 Main Business/Business Overview For more information, please visit https://www.wiseguyreports.com/sample-request/1267313-global-unmanned-aerial-vehicle-system-market-research-report-2017


News Article | May 10, 2017
Site: www.intrafish.com

The long-running tuna price-fixing case took an ugly turn on Monday with the announcement by the US Department of Justice (DOJ) that Bumble Bee Foods -- one of the 'Big three' canned tuna producers -- pleaded guilty to collusion, agreeing to pay a $25 million (€27.3 million) fine for its part in a conspiracy to fix prices between 2011-2013. It's a stunning admission, and indicates there are more pleas or convictions to come: Collusion doesn't happen without other companies, after all. So Starkist (owned by Korean giant Dongwon) and Thai Union -- at least one of them -- is most likely next to make the DOJ's greatest hits list. More troubling to Starkist and Thai Union should be the simple fact that you don't get a plea deal unless you have something good to leverage. "It's a huge sign that the government has a strong case," Diana Moss, president of Washington, DC-based think tank the American Antitrust Institute (AAI), told me Monday. The evidence could be anything from video to wiretapping to emails -- but more than just hearsay. Ironically, Moss said, it's more than likely that Thai Union's $1.5 billion (€1.4 billion attempt to acquire Bumble Bee in 2014 is what set the entire investigation off. "This was high-profile for the DOJ, and I think that was because the companies were bold enough to propose a merger when there were just three major players," Moss said. "This was a shot across the bow." Moss -- whose non-partisan, independent advocacy group promotes competition to protect consumers and businesses -- said 30 years of lax regulations on mergers and acquisitions have led to the oligarchic industry structures similar to the one in the tuna sector, bringing with it a range of problems to consumers, including fertile ground for collusion. Companies pushed through mergers that should not have been approved with promises of improving the industries they were consolidating. "But none of it happened," Moss said. "Companies are not required to prove the benefits they said they were bringing consumers." And in fact, the opposite has tended to occur. "Lower quality, lower service, less variety and of course less choice for consumers are all the result," Moss said. The DOJ had become more aggressive in recent years under President Barack Obama, in AAI's estimation. "We are seeing a pretty vigorous enforcement," Moss said. Most telling is in the fine the DOJ leveraged: while $25 million (€22.9 million) is the amount Bumble Bee is on the hook for, the company faces up to $81.5 million (€74.7 million) in fines if and when it is sold, based on "certain terms and conditions." That, essentially, is the DOJ telling the tuna giants considering merging, "don't try that again." That's bad news for private equity owner Lion Capital, who reportedly has been looking for an escape hatch from Bumble Bee for a long, long time. The DOJ plea just winnowed down the list of potential bidders dramatically. Worse, Moss said, that $25 million (€22.9 million) may end up looking small by the time private lawsuits settle out (and incidentally, attorneys in those collusion cases were rubbing their hands together Monday; their odds of winning just got dramatically better). The canned tuna sector needed a shakeup: low margins, minimal innovation, a mercury PR cloud it can't seem to escape. Tuna consumption isn't likely to recover to what it once was anytime soon. So if and when the collusion fallout is behind it, might this shakeup lead to a renaissance of innovation, variety and quality? Don't count on it, Moss said. "I don't think we have any good cases where there's been a major turnaround in a sector [following antitrust actions]," she said. What's more, she noted, "this is a troubled industry." That's an understatement, indeed. Bumble Bee's stunning admission shows tuna's troubles are just beginning. For more seafood news and updates, follow us on Facebook and Twitter or sign up for our daily newsletter


News Article | May 16, 2017
Site: www.businesswire.com

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today announced that Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular Immunology, presented additional data on its LEAPS rheumatoid arthritis (RA) vaccine candidates CEL-4000 and CEL-2000 at IMMUNOLOGY 2017, the annual meeting of the American Association of Immunologists (AAI), May 12 – 16 in Washington, D.C. The title of his poster is “Key serum cytokine markers for evaluating the efficacy of vaccine therapy in autoimmune models of rheumatoid arthritis.” The abstract can be viewed online or found through the conference website at: www.immunology2017.org. Dr. Zimmerman and the research team concluded that serum concentrations and ratios of key disease-related cytokines can predict therapeutic efficacy in different animal models of RA. The data showed that a reduced RA disease progression was observed in mice treated with LEAPS vaccines and was accompanied by decreased pro-inflammatory cytokines level and increased ratios of anti-inflammatory/regulatory to pro-inflammatory cytokines. Thus, a successful vaccine therapy appears to be associated with a ratio shift in favor of anti-inflammatory/regulatory cytokines. The ability to predict cytokine responses to therapy should allow for better design or choice of the appropriate immunomodulatory LEAPS vaccines and other therapies in RA. L.E.A.P.S. (Ligand Epitope Antigen Presentation System) is a CEL-SCI patented platform technology designed to stimulate antigen-specific immune responses in T-cells using synthetic peptides. LEAPS constructs physically link the antigenic peptide with a T-cell binding ligand and are delivered directly to the recipient by injection or through absorption onto mucosal surfaces, potentially enhancing T-cell responses to a particular antigen. CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2016. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


News Article | May 17, 2017
Site: www.businesswire.com

SEATTLE--(BUSINESS WIRE)--BIO Ventures for Global Health (BVGH), which enlists the capabilities of the biotechnology and pharmaceutical industries to tackle critical global health needs, today announced it will expand its programs to address the emerging cancer crisis in Africa. The African Access Initiative (AAI) will provide affordable, sustainable access to cancer therapeutics, enhance healthcare capacity, and foster cancer research in Africa. BVGH will launch its new initiative at the Biotechnology Innovation Organization (BIO) International Convention in San Diego on June 21, 2017. “The global health community has made important headway in tackling infectious diseases such as malaria in Africa, yet we are seeing an alarming rise in cancer and other non-communicable diseases,” said Jennifer Dent, President of BVGH. “The BVGH team will leverage our strong industry relationships, African networks, and capacity-building programs to help local healthcare professionals gain access to the cancer medicines they need and deliver educational, diagnostic, and treatment services in their communities.” “Healthcare has come a long way in Africa, but as we make inroads into some of the infectious diseases that have so plagued the continent, we must refocus our vision on the non-communicable diseases, especially cancer, that affects millions of people globally,” said Professor and Honorable Minister of Health, Isaac Adewole, Nigeria. “We must take action now to build infrastructure and develop sustainable means to provide access to cancer treatments in Africa. Our partnership with BVGH is an important step down this path.” Cancer kills 50% more Africans than malaria. GLOBOCAN reported the number of Africans who died from cancer in 2015 was 635,404. By comparison, malaria killed 394,680 Africans according to the World Health Organization (WHO) World Malaria Report 2016. The WHO expects cancer deaths in Africa will nearly double in the next two decades, while malaria is projected to continue to decline on the continent. African healthcare leaders are turning their attention to cancer and non-communicable diseases as they see the rise in cancer cases is already overwhelming many existing healthcare systems. Most African countries do not even have adequate radiation centers to treat patients. Some countries have none and lack the specialized skills necessary to deliver radiation therapy. Dramatic disparities in patient outcomes are the norm in Africa compared to middle and higher income countries. For example, 5-year net survival from breast cancer is 90% in the US, vs. 12% in Gambia. "Understanding Africa's cancer crisis is the first step in finding innovative ways of overcoming the current health systems' challenges on the continent," said Dr. Cristina Stefan, president-elect of the African Organization for Research and Training in Cancer (AORTIC). "Partnerships and collaboration with international organizations are essential in advancing and sustaining a better health care with access to oncology medicine for all Africans, as well as for responsible teaching, training and research." The initial phase of AAI will involve one to three hospitals in each of six African countries – Cameroon, Côte d'Ivoire, the Democratic Republic of the Congo, Kenya, Nigeria, and Senegal. BVGH will assess the cancer treatment and R&D needs of each participating hospital and country; engage pharmaceutical and biotechnology companies with complementary capabilities, priorities and interests; and broker innovative partnership and custom pricing agreements among the hospitals, governments, and companies to address the identified needs. Details of the AAI program along with a joint BVGH/AORTIC white paper on the state of cancer care in Africa will be presented at the BIO meeting in June. BVGH will also be hosting its third annual Africa Pavilion at the BIO Convention, featuring representatives from AORTIC, the European & Developing Countries Clinical Trials Partnership (EDCTP) Networks of Excellence, the East African Health Research Commission (EAHRC), and leading African research organizations. Participation in the 2017 Africa Pavilion will represent 24 African countries. BVGH is a results-oriented nonprofit organization based in Seattle, Washington, USA whose mission is to engage private industry in global health initiatives. BVGH engages global health stakeholders in partnerships to accelerate the development of new drugs, vaccines, and diagnostics that address the unmet medical needs of the developing world. Working at the crossroads of the biopharmaceutical industry and global health, BVGH creates customized programs that fit the needs and capacity of partners and impact health in measurable ways. About the African Organization for Research and Training in Cancer (AORTIC) AORTIC seeks to become the Continent’s pre-eminent non-profit organisation working for cancer control. AORTIC will achieve this through the facilitation of research and training as well as the provision of relevant and accurate information on the prevention, early diagnosis, treatment, and palliation of cancer. Our organisation is dedicated to providing all Africans with these benefits, as well as to increasing public awareness of cancer and reducing the stigma associated with it.


News Article | May 22, 2017
Site: www.thefishsite.com

A £1 million innovation fund aimed at small to medium enterprises (SMEs) working in the aquaculture supply chain in the Highlands and Islands is now open to applications. Announced in March, the 30-month pilot programme, Accelerating Aquaculture Innovation (AAI) is led by HIE and delivered in partnership with Scottish Aquaculture Innovation Centre (SAIC). It offers SMEs the opportunity of match funding to help commercialise innovative new processes, products, services or technologies. The programme has the potential to boost industry turnover in the region by £8 million and create up to 50 jobs. The value of innovative concepts can take different forms – financial, commercial, economic, social or public – but it must be measurable, and it must benefit both the industry and the Scottish economy. Aquaculture is a priority sector for HIE and is estimated to contribute as much as £1.8 billion turnover a year to the Scottish economy, supporting 8,000 jobs. The Aquaculture Growth Strategy 2030, A Strategic Plan for Farming Scotland’s Seas, states the industry has potential for this to increase to £3.6 billion and 18,000 jobs by 2030. Elaine Jamieson, Head of Food and Drink at HIE, said: “The full range of projects, from £25,000 to £1 million, will be considered. Where applications are successful, the AAI programme could typically provide up to half the project cost. “Where applications don’t quite meet the programme criteria, the AAI team will point SMEs to more suitable support avenues so that they still receive the help they need to develop their concept.” Jason Cleaversmith, Aquaculture Innovation Director at SAIC, added: “Since news of the AAI programme was first announced, we have had informal discussions with over 20 aquaculture SMEs in the HIE region interested in exploring innovative new concepts. With the fund now officially open for applications, we look forward to progressing those discussions – and others – to the next stage, and have deliberately kept the process as straightforward and fleet of foot as possible.” Companies can apply for AAI funding by submitting a short Expression of Interest (EOI) form. This will then be assessed by the AAI team and, if successful, the submitting company will be invited to complete a fuller application. Full details on how to apply, along with downloadable forms and guidance notes, are available here.


-- Cavignac & Associates, a downtown San Diego-based risk management and insurance brokerage firm, has hired Nicole Laforteza as an account administrator within the agency's Employee Benefits Department, announced Jeffrey W. Cavignac, CPCU, RPLU, CRIS, company principal and founder.Laforteza's primary responsibility is to assist the department's account manager with daily service activities for each client's benefit offerings.  Specifically, she coordinates requests for proposals and prepares quotations for new and renewal coverage; compiles open enrollment materials; creates spreadsheets, presentations and proposals for new and renewal business; and prepares packages of material for open enrollment meetings, sometimes handling those meetings if requested.Prior to joining Cavignac & Associates, Laforteza served as a bookkeeper and administrative assistant for Dunne & Dunne, LLP, where she worked for five-and-a-half years.  There she maintained all client accounts, prepared client invoices, collected replenishments and assisted all of the firm's associate attorneys.A graduate of California State University, Long Beach, Laforteza holds a Bachelor of Arts degree in journalism, with an emphasis in public relations and minor in communication studies.  Currently she is a graduate student at National University, where she is working toward her graduate degree in strategic communication.Born in the Philippines and raised in San Diego, Laforteza currently resides in the San Diego community of Chula Vista.  She enjoys various sports, especially basketball, running and hiking.  Her other leisure time activities include playing with her three dogs, photography, and going on spontaneous adventures to Orange County, Los Angeles, and hidden spots within San Diego.Founded in 1992, Cavignac & Associates is a leading risk management and commercial insurance brokerage firm providing a broad range of insurance and expertise to design and construction firms, as well as to law firms, real estate-related entities, manufacturing companies and the general business community. Company principals are Jeffrey W. Cavignac, CPCU, ARM, RPLU, CRIS, MLIS; James P. Schabarum II, CPCU, AFSB; Scott A. Bedingfield, AAI, CIC, CRIS; Patrick Casinelli, RHU, REBC, CHRS; Matthew Slakoff, CIC, CRIS; and Matthew Noonan, RHU, CIC, CHRS, CCWS. The firm employs a staff of more than 50 at offices located at 450 B Street, Suite 1800, San Diego, Calif., 92101.  More information about the company can be found at www.cavignac.com


News Article | June 22, 2017
Site: www.prnewswire.com

Tata Elxsi will also enable AAI to set a team and create a process to design and implement world-class, customer-centric information and wayfinding system. This will cover the entire passenger journey right from parking to boarding the plane, to making the spaces efficient and user-friendly. The design will be in line with the global standards and Tata Elxsi will set the guidelines/standards for all future airports. Tata Elxsi has already started the work on creating an intuitive, customer-centric wayfinding system and developing a unique image for several airport terminals. Narendra Ghate - Chief Designer, Service Design, Tata Elxsi said, "Having worked in the past on redefining the passenger experience for some leading airports in India, gave Tata Elxsi an edge. We are happy that AAI chose us as their strategic design consultant. We look forward to help AAI in creating a seamless and enhanced travel experience for all passengers for the above said airports." Sudhir Raheja - Member Planning, Airports Authority India, said, "We were looking out globally for a company who can understand what the people in India need. AAI is happy to find a world-class organization like Tata Elxsi who can integrate Design and Technology, understand customer experience, and can help AAI to set guidelines for all future airports at par with the global standards. We are excited to see the change Tata Elxsi will bring to the airports in India, and the passengers that travel within." Tata Elxsi has already commenced work across the shortlisted 10 airports - Goa, Kolkata, Varanasi, Lucknow, Chennai, Bhubaneshwar, Pune, Trivandrum, Coimbatore and Guwahati. Tata Elxsi is a fully-integrated global design and technology consultancy, creating innovative products, services and experiences to build brands and help businesses grow. By intersecting design and technology, Tata Elxsi helps clients globally to bring new ideas and products to market. Its services span across research and strategy, all the way up to Design, Visualization - augmented reality and virtual reality to technology implementation and systems integration. Its services span across consumer research and strategy, branding and graphics, product design, packaging design, service design, user experience design, transportation design, 3D prototyping, visualization and manufacturing support. With a multi-disciplinary team of over 400 researchers, designers, brand specialists and engineers, Tata Elxsi offers innovative, cost-effective and scalable solutions that enable brands to differentiate and win. AAI manages 126 Airports, including 21 International Airports (3 Civil Enclaves), 8 Customs Airports (4 Civil Enclaves), 78 Domestic Airports and 19 other Civil Enclaves. AAI is entrusted with the responsibility of developing, upgrading, expanding, maintaining and managing civil aviation infrastructure on both the ground and air space for India. In addition, AAI provides Air Navigation Services (ANS) at all civil airports in the country. AAI manages the designated Indian airspace measuring 2.8 square nautical miles and oceanic airspace measuring 1.75 million square nautical miles.


News Article | June 22, 2017
Site: www.prnewswire.co.uk

Tata Elxsi will also enable AAI to set a team and create a process to design and implement world-class, customer-centric information and wayfinding system. This will cover the entire passenger journey right from parking to boarding the plane, to making the spaces efficient and user-friendly. The design will be in line with the global standards and Tata Elxsi will set the guidelines/standards for all future airports. Tata Elxsi has already started the work on creating an intuitive, customer-centric wayfinding system and developing a unique image for several airport terminals. Narendra Ghate - Chief Designer, Service Design, Tata Elxsi said, "Having worked in the past on redefining the passenger experience for some leading airports in India, gave Tata Elxsi an edge. We are happy that AAI chose us as their strategic design consultant. We look forward to help AAI in creating a seamless and enhanced travel experience for all passengers for the above said airports." Sudhir Raheja - Member Planning, Airports Authority India, said, "We were looking out globally for a company who can understand what the people in India need. AAI is happy to find a world-class organization like Tata Elxsi who can integrate Design and Technology, understand customer experience, and can help AAI to set guidelines for all future airports at par with the global standards. We are excited to see the change Tata Elxsi will bring to the airports in India, and the passengers that travel within." Tata Elxsi has already commenced work across the shortlisted 10 airports - Goa, Kolkata, Varanasi, Lucknow, Chennai, Bhubaneshwar, Pune, Trivandrum, Coimbatore and Guwahati. Tata Elxsi is a fully-integrated global design and technology consultancy, creating innovative products, services and experiences to build brands and help businesses grow. By intersecting design and technology, Tata Elxsi helps clients globally to bring new ideas and products to market. Its services span across research and strategy, all the way up to Design, Visualization - augmented reality and virtual reality to technology implementation and systems integration. Its services span across consumer research and strategy, branding and graphics, product design, packaging design, service design, user experience design, transportation design, 3D prototyping, visualization and manufacturing support. With a multi-disciplinary team of over 400 researchers, designers, brand specialists and engineers, Tata Elxsi offers innovative, cost-effective and scalable solutions that enable brands to differentiate and win. AAI manages 126 Airports, including 21 International Airports (3 Civil Enclaves), 8 Customs Airports (4 Civil Enclaves), 78 Domestic Airports and 19 other Civil Enclaves. AAI is entrusted with the responsibility of developing, upgrading, expanding, maintaining and managing civil aviation infrastructure on both the ground and air space for India. In addition, AAI provides Air Navigation Services (ANS) at all civil airports in the country. AAI manages the designated Indian airspace measuring 2.8 square nautical miles and oceanic airspace measuring 1.75 million square nautical miles.


News Article | February 15, 2017
Site: www.prweb.com

Asian Atlantic Industries (AAI), a privately held global independent electronics distributor, is improving its customers’ experience and amplifying its brand awareness by launching its newly redesigned website with accompanying O2 Portal explainer video. In addition to a fresh and modern look, the new website boasts a short, yet informative video explaining the benefits of the company’s powerful O2 Portal. Created by AAI, the O2 Portal is a patented inventory management tool that allows OEMs and CEMs to view inventory and demand, helping customers move excess inventory. The explainer video simplistically describes how the O2 Portal provides cost savings (+PPV opportunities), shortage fulfillment, and excess cost recovery opportunities for OEMs and CEMs in an anonymous and secure location. Other customer-centric highlights of the new website include: “A major factor behind our decision to build a new website was to increase our customers’ understanding of our full range of services,” commented Tom Mahoney, AAI’s chief executive officer. “The improved navigation of the site allows the viewer to easily find the information they need make informed decisions, and the explainer video simply tells the story of the O2 Portal’s value proposition. Additionally, the website and video are effective marketing tools for the company and will help us gain more traction in the semiconductor and finished goods marketplaces.” With more than $100 million in annual revenue and 15 locations worldwide, AAI’s Finished Goods and Integrated Circuits Divisions utilize the management team’s combined industry experience to deliver exceptional service while accommodating customer needs. The Finished Goods Division facilitates a wide range of product requests of any quantity, while the Integrated Circuits Division distributes electronic components to large OEM and contract manufacturers, and helps create positive price variance, fill shortages, and sell excess inventory. Founded in 1998, Asian Atlantic Industries (AAI) is a leading, privately held global independent electronics distributor offering timely and cost effective solutions. Headquartered in a state-of-the-art facility in New Hampshire with global operations, AAI’s Integrated Circuits and Finished Goods Divisions are committed to continuously delivering world-class quality and service. For more information, please visit http://www.aai-inc.com.

Loading AAI collaborators
Loading AAI collaborators